Avalere Health Expands to Japan
Analysis based on 6 articles · First reported May 11, 2026 · Last updated May 11, 2026
The expansion of Avalere Health into Japan is expected to positively impact the Japanese healthcare market by providing integrated solutions to biopharmaceutical companies. This move could lead to increased competition and innovation in the Japanese domestic drug market, particularly in oncology, diabetes, immunology, and rare disease areas.
Avalere Health, a global strategic partner for the healthcare industry, announced the launch of its Japan office in Tokyo on May 11, 2026. This expansion, led by industry veteran Junji Yokokawa, aims to support Japanese biopharmaceutical companies across the product lifecycle with integrated market access, medical, and marketing solutions. CEO Amar Urhekar highlighted the explosive growth in the Japanese domestic drug market, especially in oncology, diabetes, immunology, and rare disease areas, where Avalere Health possesses deep expertise. The new office will address challenges such as an aging society, financial barriers for patients, and rural access gaps in Japan's advanced healthcare system.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard